Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (DRV/c) are newly approved once daily fixed-dose protease inhibitor combinations for the treatment of HIV-1 infection. Studies in healthy volunteers have established bioequivalence between cobicistat and ritonavir as pharmacoenhancers of both at...

Descripción completa

Detalles Bibliográficos
Autores principales: Crutchley, Rustin D, Guduru, Rakesh C, Cheng, Amy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790521/
https://www.ncbi.nlm.nih.gov/pubmed/27022304
http://dx.doi.org/10.2147/HIV.S99063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790521/
https://www.ncbi.nlm.nih.gov/pubmed/27022304
http://dx.doi.org/10.2147/HIV.S99063

Ejemplares similares